ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,296.00
-0.41%
S&P ASX All Technology
3,854.60
-0.04%
Brent Oil
74.055
1.15%
US Dollar vs AUD
1.56961
-0.01%
Bitcoin
100,478.93
0.42%
Pepperstone
Advertisement
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Canada
  5. TSX

  6. Medicenna Therapeutics Corp (MDNA) Share Price

Medicenna Therapeutics Corp

Medicenna Therapeutics Corp (MDNA)

TSX
1.81
0.02
(1.12%)
Closed 13 December 8:12AM
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
1.81
Bid
1.75
Offer
1.88
Volume
46,749
1.73 Day's Range 1.83
0.38 52 Week Range 2.98
Market Cap
126.043M
Previous Close
1.79
Open
1.79
Last Trade
6
@
1.81
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
80,470
Shares Outstanding
69,637,000
Dividend Yield
-
PE Ratio
-4.79
Earnings Per Share (EPS)
-0.37
Revenue
-
Net Profit
-25.47M

About Medicenna Therapeutics Corp

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.medicenna.com
Headquarters
Toronto, Ontario, Can
Founded
-
Medicenna Therapeutics Corp is listed in the Biological Pds,ex Diagnstics sector of the Toronto Stock Exchange with ticker MDNA. The last closing price for Medicenna Therapeutics was $1.79. Over the last year, Medicenna Therapeutics shares have traded in a share price range of $ 0.38 to $ 2.98.

Medicenna Therapeutics currently has 69,637,000 shares in issue. The market capitalisation of Medicenna Therapeutics is $124.65 million. Medicenna Therapeutics has a price to earnings ratio (PE ratio) of -4.79.

Ask ADVFN Intelligence (AI)

MDNA Latest News

More News

Medicenna Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA® (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study

70-year-old patient with advanced chemo-refractory anal cancer achieves complete response (CR) in 8 weeks when treated with MDNA11 in combination with Merck’s (known as MSD outside of the US and...

05 December 2024
GlobeNewswire Inc.

Updated MDNA11 Monotherapy and Combination Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to be Presented at the 2024 Immunotherapy Bridge Conference

TORONTO and HOUSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company...

27 November 2024
GlobeNewswire Inc.

Medicenna Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO)

MDNA11 shows significant survival benefits in preclinical glioblastoma models, expanding CD8+ T and NK cells Bizaxofusp selectively targets human tumor cells and immune-suppressive cells...

25 November 2024
GlobeNewswire Inc.

Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update

MDNA11 continues to show best-in-class potential in the ABILITY-1 study with an objective response rate (ORR) of 30% in the monotherapy dose expansion cohort among patients with cancer progression...

15 November 2024
GlobeNewswire Inc.

Medicenna Announces Upcoming Presentations at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) and the 2024 San Antonio Breast Cancer Symposium (SABCS)

TORONTO and HOUSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company...

13 November 2024
GlobeNewswire Inc.

Medicenna Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA® (pembrolizumab) at the 39th Annual Meeting of SITC

Single-agent MDNA11 shows a 30% objective response rate (3 of 10) in the monotherapy dose expansion cohort among patients with advanced and/or metastatic solid tumors who had disease progression...

11 November 2024
GlobeNewswire Inc.

Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

   MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” BiSKIT (Bifunctional SuperKine for ImmunoTherapy), engineered to deliver an anti-PD1-IL-2 Superkine (anti-PD1-IL-2SK) to the tumor...

09 November 2024
GlobeNewswire Inc.

OTC Markets Group Welcomes Medicenna Therapeutics Corp. to OTCQX

NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Medicenna...

15 October 2024
GlobeNewswire Inc.

Medicenna to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Updated clinical results to be presented from the ongoing Phase 1/2 ABILITY-1 study of MDNA11 in advanced or metastatic solid tumors Preclinical data on MDNA113, Medicenna's first-in-class...

04 October 2024
GlobeNewswire Inc.

Medicenna Announces Results of Annual Meeting of Shareholders

TORONTO and HOUSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on...

27 September 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.127.100591715981.692.141.69969311.94821884CS
40.116.470588235291.72.141.27738081.72339623CS
12-0.24-11.70731707322.052.621.27804701.99519731CS
26-0.71-28.17460317462.522.631.27815822.04549512CS
521.365306.7415730340.4452.980.381020421.84288297CS
156-0.32-15.02347417842.132.980.215635411.44827764CS
2600.15.847953216371.717.250.215743842.76068262CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BNGBengal Energy Ltd
$ 0.015
(50.00%)
10k
IVQ.UInvesque Inc
US$ 0.10
(25.00%)
13.2k
IVQInvesque Inc
$ 0.14
(21.74%)
501
APLIAppili Therapeutics Inc
$ 0.04
(14.29%)
51k
KRNKarnalyte Resources Inc
$ 0.13
(13.04%)
740
BCTBriaCell Therapeutics Corp
$ 0.95
(-40.25%)
2.03k
BABYElse Nutrition Holdings Inc
$ 0.015
(-25.00%)
1.32M
MSCLSatellos Bioscience Inc
$ 0.90
(-24.37%)
345.5k
DIAMStar Diamond Corporation
$ 0.03
(-14.29%)
310k
PPRPrairie Provident Resources Inc
$ 0.03
(-14.29%)
2.13k
CNQCanadian Natural Resources Ltd
$ 45.03
(-2.24%)
14.94M
CVECenovus Energy Inc
$ 21.49
(-1.01%)
8.66M
TTelus Corp
$ 20.99
(-2.42%)
8.41M
MFCManulife Financial Corporation
$ 43.85
(-1.68%)
6.97M
BCEBCE Inc
$ 36.75
(-0.19%)
6.53M

Discussion

View Full Feed
sab63090 sab63090 1 minute ago
I would hope that the effect of COVID and drop out rates would be at least touched upon if proven to be fact.
AVXL
MrSmithLWLG MrSmithLWLG 2 minutes ago
THEY DONT HAHE A PACKAGING PARTNER TO SCALE WITH ! Call / email Atikem. I dare you PROTO! You won’t because you don’t want the truth.

X……just like VHC, another one you got sooo WRONG. And that private deal we invested in, BUST !
LWLG
StayHumble StayHumble 2 minutes ago
yes!💹Historic $HIRU Xpert interest💹https://ih.advfn.com/stock-market/USOTC/hiru-pk-HIRU/historical
HIRU
MusicExec MusicExec 3 minutes ago
Thanks for clarifying 
SONG
Money hunt Money hunt 3 minutes ago
Lilly lays down $1B to be ‘first in biology’ with obesity gene therapies
The deal, which targets metabolic diseases, is one of a few by Big Pharma to develop lncRNA therapies.


https://www.pharmavoice.com/news/eli-lilly-biology-lncrna-haya-obesity/726356/
ELAB
glenn1919 glenn1919 3 minutes ago
EVGO.....NIXX....RZLV....MULN..................https://stockcharts.com/h-sc/ui?s=MULN&p=D&yr=0&mn=2&dy=12&id=p84071410134
EVGO MULN NIXX
sab63090 sab63090 5 minutes ago
k9uwa
You forgot to mention that the weather is the most consistently good for people who want good weather! Yes, Morgan Stanley is where I retired from after 26 years there, great times with Mack the knife & Phil Purcell....7 with Merrill Intl /Germany and 6 with PaineWebber (now UBS) USA.
AVXL
INFINITI INFINITI 5 minutes ago
Offering Closed now lets move this bad boy back up $$$$$
PALI
glenn1919 glenn1919 5 minutes ago
NIXX.....MOBX.....NRGV........MULN.....................https://stockcharts.com/h-sc/ui?s=MULN&p=D&yr=0&mn=2&dy=12&id=p84071410134
MOBX MULN NIXX
HD2001 HD2001 5 minutes ago
Maybe xalles can dump another 100 million shares on fake companies to divest them again it's seems to be the easy way to screw shareholders.
XALL
100lbStriper 100lbStriper 5 minutes ago
NLST HOME PAGE if your interested in keeping up with whats going on..... https://netlist.com/about/
NLST
100lbStriper 100lbStriper 7 minutes ago
our sk product line........ https://netlist.com/products/sk-hynix/
NLST
capgain capgain 8 minutes ago
Wow, I do. That was a while ago, I figured she was lying the whole time.
Jack_Bolander Jack_Bolander 8 minutes ago
BAD NEWS for BALLARD !

https://cleantechnica.com/2024/12/12/hydrogen-ships-are-seeing-same-pattern-as-all-hydrogen-fleets/
BLDP
Jack_Bolander Jack_Bolander 9 minutes ago
EVEN MORE BAD NEWS !

https://cleantechnica.com/2024/12/12/hydrogen-ships-are-seeing-same-pattern-as-all-hydrogen-fleets/
PLUG
iamthe walrus iamthe walrus 9 minutes ago
CORETEC WINS VOTE AT KIB PLUG ENERGY Extraordinary Shareholders' Meeting !!! Appointment of 4 Directors passes. A new CEO of Kib Plug Energy will be appointed ( We will re-disclose the new CEO as soon as the Board of Directors appoints a new CEO. )

Outcome of Extraordinary Sharehold
CRTG
100lbStriper 100lbStriper 9 minutes ago
nlst... i must say the product page is getting updated, this is new as well........ https://netlist.com/products/lightning-ddr5-dimm/
NLST
SCAMBUSTERKING SCAMBUSTERKING 10 minutes ago
The $ isnt added till he sells. He hadnt started hammering the bid at vol till q3
SONG
MrLWLG101 MrLWLG101 10 minutes ago
The intellectual property (IP) rights for Lightwave Logic's technologies belong to the company itself, Lightwave Logic, Inc., and not personally to Dr. Michael Lebby. Dr. Lebby, as the CEO and a key figure in the company's technological development, contributes significantly to Lightwave Logic's adv
LWLG
HD2001 HD2001 10 minutes ago
Looks like cashx is gone xalles is shrinking instead of growing most likely due to the terrible management at xalles from top to bottom. https://xalles.com/wp-content/uploads/2024/12/Xalles-Corporate-Structure-Dec-13-2024-1.jpg
XALL
Gooddolphin Gooddolphin 11 minutes ago
One thing for sure.. NSAV doesn't have much room to go to .00000.

I'm riding it out to the end.... (added more yesterday. :)
.
NSAV
glenn1919 glenn1919 11 minutes ago
AEI..............................https://stockcharts.com/h-sc/ui?s=AEI&p=W&b=5&g=0&id=p86431144783
AEI
Jack_Bolander Jack_Bolander 11 minutes ago
MORE BAD NEWS !

https://cleantechnica.com/2024/12/12/hydrogen-ships-are-seeing-same-pattern-as-all-hydrogen-fleets/
sab63090 sab63090 12 minutes ago
Me too
AVXL
Frigger Frigger 14 minutes ago
Very confused. The Termination of Security was filed yesterday on Edgar. This morning Neutra Posted on X that it will return to pink shortly with a year-end update before the 31st.
NTRR

Your Recent History

TSX
MDNA
Medicenna Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved